RecruitingPhase 1NCT06080061

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Sponsor

Stanford University

Enrollment

45 participants

Start Date

Oct 25, 2023

Study Type

INTERVENTIONAL

Conditions

Lung Cancer

Summary

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
ECOG performance status of 0-2
Age \> 18 years old
Ability to understand and the willingness to personally sign the written IRB approved informed consent document
Estimated life expectancy of 12 weeks or longer

Exclusion Criteria5

Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
Age \< 18 years old
Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
Diagnosis of interstitial pulmonary fibrosis
Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields

Interventions

RADIATIONHypofractionated accelerated radiation therapy

Hypofractionated accelerated radiation therapy

Locations(1)

Stanford University

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06080061

Related Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828763 locations